Similar articles

• Are high-potency statins in low dose "strong statins"?

  Berent R, Sinzinger H. Berent R, et al. Heart Vessels. 2013 May;28(3):412. doi: 10.1007/s00380-012-0255-4. Epub 2012 May 9. Heart Vessels. 2013. PMID: 22570139 No abstract available.
• Effects of lipid-lowering therapy with strong statin on serum polyunsaturated fatty acid levels in patients with coronary artery disease.

  Kurisu S, Ishibashi K, Kato Y, Mitsuba N, Dohi Y, Nishioka K, Kihara Y. Kurisu S, et al. Heart Vessels. 2013 Jan;28(1):34-8. doi: 10.1007/s00380-011-0213-6. Epub 2011 Dec 21. Heart Vessels. 2013. PMID: 22187148
• Clinical review 141: lipids and atherosclerosis: lessons learned from randomized controlled trials of lipid lowering and other relevant studies.

  Kreisberg RA, Oberman A. Kreisberg RA, et al. J Clin Endocrinol Metab. 2002 Feb;87(2):423-37. doi: 10.1210/jcem.87.2.8057. J Clin Endocrinol Metab. 2002. PMID: 11836262 Review. No abstract available.
• Getting more people on statins.

  Roberts WC. Roberts WC. Am J Cardiol. 2002 Sep 15;90(6):683-5. doi: 10.1016/s0002-9149(02)02590-0. Am J Cardiol. 2002. PMID: 12231110 No abstract available.
• Statins and coronary artery disease: clinical evidence and future perspective.

  Biasucci LM, Stefanelli A, Biasillo G. Biasucci LM, et al. Minerva Cardioangiol. 2012 Apr;60(2):147-56. Minerva Cardioangiol. 2012. PMID: 22495163 Review.